VeroVaccines raises €3.1M Seed round
7 August 2018· Halle (Saale), Germany· health, biotech, b2b, deep_hardware
The funding, provided through the GO-Bio program and supplemented by a private investor consortium, will be used over three years to optimize yeast strains and generate data for vaccine approval
Investors
LeadGO-Bio
Also participating
High-Tech GründerfondsBamac GmbH
About VeroVaccines
Stage
Bridge
Headquarters
Halle (Saale), Germany
Founded
2021
Team Size
6–20
Sectors
healthbiotechb2bdeep_hardware
Source: https://www.campus-halensis.de/artikel/verovaccines-impfstoffentwickler-auf-erfolgskurs/